News | December 05, 2006

U.S. Should Merge Anemia Drug, Dialysis Costs: Report

Medicare, the U.S. insurance program for elderly and disabled Americans, should lump the price of anemia drugs with overall payments for kidney dialysis services to improve efficiency and contain costs, according to a government report released on Tuesday.

Medicare's method of paying separately for anemia drugs, primarily Amgen Inc.'s Epogen, and for dialysis services is a concern as use grows, the Government Accountability Office (GAO) said. Medicare covers about 43 million Americans and spent $2 billion on Epogen in 2005.

The report by the investigative arm of Congress was released ahead of a U.S. House of Representatives Ways and Means Committee hearing on Wednesday to discuss use of the drugs and growing government spending on dialysis patients.

Medicare has taken steps over the years to address its payment policy for kidney disease treatment, but lawmakers may need to intervene, the GAO said.

"The Congress should consider establishing a bundled payment system for all (end-stage renal disease) services, including drugs, as soon as possible," the GAO said.

Analysts have said they do not expect any major changes in reimbursement after the hearing. Still, attempts to curb Medicare payments could cause investor unease over Amgen, which gets nearly half its revenue from sales of two anemia drugs.

Critics have said the Medicare price structure drives up use of the drugs, and the program does not limit the dose doctors can administer with government reimbursement. Recent studies also linked higher doses of anemia drugs with heart-related complications.

Industry analysts have said bundling anemia drug reimbursement with dialysis payments would remove the profit incentive for doctors to use the drugs.

Currently, the U.S. Medicare program reimburses dialysis providers for Amgen's Epogen at the average sales price (ASP) plus a 6 percent premium. Under that formula, the higher a drug is priced, the more money doctors make.

"The ASP method relies on market forces to moderate manufacturers' prices, however, Epogen is the product of a single manufacturer and has no competitor products," the GAO said.

Medicare bundles drug prices with other costs for most other types of therapies it covers.

Separately, Centers for Medicare and Medicaid Services Acting Administrator Leslie Norwalk said the agency agreed such reforms would help promote efficiency and flexibility for dialysis centers.

Amgen's Aranesp, a longer lasting anemia drug, is not generally marketed to dialysis clinics, according to the GAO. Johnson and Johnson's Procrit drug also treats anemia in kidney patients but is not approved for those not on dialysis.

Shares of Amgen fell as much as 3 percent when news of the GAO report trickled out on Friday. They closed down 9 cents, or less than 1 percent on Tuesday after the report's release.

Related Content

Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Results of the vertebrae-based analysis (383 vertebrae in 34 patients) for detection of BME.

Results of the vertebrae-based analysis (383 vertebrae in 34 patients) for detection of BME.

Sponsored Content | Case Study | Computed Tomography (CT) | November 06, 2018
The following is a summary of a study published in the
The NeuViz 16 Essence from Neusoft Medical Systems.

The NeuViz 16 Essence from Neusoft Medical Systems.

Feature | Computed Tomography (CT) | November 05, 2018 | By Melinda Taschetta-Millane
According to an industry mark...
Carestream Spotlights Healthcare IT and Imaging Systems at RSNA 2018
News | Information Technology | October 31, 2018
Carestream announced it will be displaying several imaging and healthcare information technology (IT) offerings at the...
IMRIS, Siemens Strengthen Collaboration in Hybrid OR Neurosurgical Market
News | Hybrid OR | October 24, 2018
IMRIS, Deerfield Imaging, in partnership with Siemens Healthineers, announced a strengthened collaboration to advance...
Fujifilm Unveils FCT Embrace CT System for Oncology
Technology | Computed Tomography (CT) | October 23, 2018
Fujifilm Medical Systems U.S.A. Inc. recently introduced the FCT Embrace computed tomography (CT) system. Powered by...
The Aquilion Precision CT system from Canon offers very high resolution imaging, which may aid in cancer detection and improved treatment planning in radiation oncology. #ASTRO2018 #ASTRO #ASTRO18

The Aquilion Precision CT system from Canon offers very high resolution imaging, which may aid in cancer detection and improved treatment planning in radiation oncology. 

News | Computed Tomography (CT) | October 19, 2018
October 19, 2018 – At the 2018 American Society of...